Lp(a), a new lipid frontier in CV risk management & target for therapy

Episodes 1-4 of 4

• 

  RestartResume

  Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

  RestartResume

  Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

  Lp(a), a new lipid frontier in CV risk management & target for therapy

  Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

  • 

    

    Prof. Erik Stroes, MD

• 

  RestartResume

  Is there a role for PCSK9 inhibition in patients with high Lp(a)?

  RestartResume

  Is there a role for PCSK9 inhibition in patients with high Lp(a)?

  Lp(a), a new lipid frontier in CV risk management & target for therapy

  Is there a role for PCSK9 inhibition in patients with high Lp(a)?

  • 

    

    Prof. Vera Bittner, MD

• 

  RestartResume

  Novel strategies to lower Lp(a)

  RestartResume

  Novel strategies to lower Lp(a)

  Lp(a), a new lipid frontier in CV risk management & target for therapy

  Novel strategies to lower Lp(a)

  • 

    

    Prof. Sam Tsimikas

• 

  RestartResume

  Why worry about high Lp(a) and how to assess Lp(a) levels?

  RestartResume

  Why worry about high Lp(a) and how to assess Lp(a) levels?

  Lp(a), a new lipid frontier in CV risk management & target for therapy

  Why worry about high Lp(a) and how to assess Lp(a) levels?

  • 

    

    Pia Kamstrup, MD, PhD